Conflict of interest: MJOD is a member of the ACCP Antithrombotic Guidelines (Stroke Chapter). ERM is the recipient of Boehringer-Ingelheim Research Fellowship. J.W.E. has received honoraria and research support from Bayer Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen, and Pfizer.
Novel oral anticoagulants: A focused review for stroke physicians
Version of Record online: 22 OCT 2013
© 2013 The Authors. International Journal of Stroke © 2013 World Stroke Organization
International Journal of Stroke
Special Issue: Global Stroke Statistics Edition
Volume 9, Issue 1, pages 71–78, January 2014
How to Cite
McGrath, E. R., Eikelboom, J. W., Kapral, M. K. and O'Donnell, M. J. (2014), Novel oral anticoagulants: A focused review for stroke physicians. International Journal of Stroke, 9: 71–78. doi: 10.1111/ijs.12158
Funding: Health Research Board of Ireland Research Fellowship.
- Issue online: 19 DEC 2013
- Version of Record online: 22 OCT 2013
- Health Research Board of Ireland Research Fellowship
Table S1. Pharmacological properties of dabigatran, apixaban and rivaroxaban.
Table S2. Results of phase III trials of novel anticoagulants in atrial fibrillation.
Table S3. CHADS2 scores of patients included in RE-LY, ROCKET-AF, ARISTOTLE and AVERROES.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.